Mark G. Kris, MD, FACP, FACCP
Chief, Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Cornell University Medical College
New York, NY

Dr. Kris is an Attending Physician in the Thoracic Oncology Service at Memorial Hospital, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. He is the first incumbent of the William and Joy Ruane Chair in Thoracic Oncology. Dr. Kris is a Professor of Medicine at the Weill Cornell Medical College in New York, NY. Since 2012, he has served as the Lead Physician for the Memorial Sloan Kettering - IBM Watson Collaboration.

Dr. Kris graduated from Fordham University in Bronx, NY. After receiving his Medical Degree from Weill Cornell Medical College, he served as chief medical resident and fellow in Medical Oncology at Memorial Sloan Kettering Cancer Center.

Dr. Kris is author or coauthor of over 300 original scientific publications. He served as a member of the guideline panels on non-small cell lung cancers and antiemetics for the National Comprehensive Cancer Center Network from 1995-2015. Dr. Kris serves as Co-chair of the guideline panel for adjuvant chemotherapy and radiation for non-small cell lung cancers, and antiemetics for the American Society of Clinical Oncology. He is a Fellow of the American College of Physicians, The American College of Chest Physicians, and The American Society of Clinical Oncology. He received the first American Society of Clinical Oncology Humanitarian Award in 2011. Dr. Kris also received the Annie Blount Storrs Award from Calvary Hospital in 2014.

Dr. Kris is a specialist in lung cancers and other tumors arising in the chest. He is particularly interested in developing ways to choose treatments for patients based on molecular characteristics of their tumor specimens. His research also includes the evaluation of new anticancer agents (particularly those targeting lung cancers), multimodality therapy (using surgery, radiation and drugs together to improve outcomes for individuals with thoracic cancers), and the training of the IBM Watson cognitive computer to assist physicians and patients in choosing the best treatments.